Artificial Intelligence Predicts Next Session’s Price Change For Amerco, Petroleo Brasileiro, Ecopetrol S.A.

(VIANEWS) – Today, the Innrs artificial intelligence algorithm suggests a high probability of discovering the approximate price for tomorrow of Amerco UHAL, Petroleo Brasileiro PBR and others.

Via News will regularly fact-check this AI algorithm that aims to consistently predict the next session price and next week’s trend of financial assets.

Innrs provides A.I.-based statistical tools to help investors make decisions. The table below shows the financial assets predicting price, ordered by the highest expected accuracy.

Innrs officials say this tool helps investors make better-informed decisions, supposedly used alongside other relevant financial information and the specific trader strategy.

In the next session, Via News will report the finding on the algorithm precision.

1. Amerco (UHAL)

Shares of Amerco dropped by a staggering 13.33% in from $65.88 to $57.10 at 19:21 EST on Tuesday, after two successive sessions in a row of losses. NASDAQ is jumping 1.58% to $11,860.11, following the last session’s upward trend.

U-Haul Holding Company operates as a do-it-yourself moving and storage operator for household and commercial goods in the United States and Canada. The company's Moving and Storage segment rents trucks, trailers, portable moving and storage units, specialty rental items, and self-storage spaces primarily to the household movers; and sells moving supplies, towing accessories, and propane. It also provides uhaul.com, an online marketplace that connects consumers to independent Moving Help service providers and independent self-storage affiliates; auto transport and tow dolly options to transport vehicles; and specialty boxes for dishes, computers, flat screen television, and sensitive electronic equipment, as well as tapes, security locks, and packing supplies. This segment rents its products and services through a network of approximately 2,100 company operated retail moving stores and 21,100 independent U-Haul dealers. As of March 31, 2022, it had a rental fleet of approximately 186,000 trucks, 128,000 trailers, and 46,000 towing devices; and 1,844 self-storage locations with approximately 876,000 rentable storage units. The company's Property and Casualty Insurance segment offers loss adjusting and claims handling services. It also provides moving and storage protection packages, such as Safemove and Safetow packages, which offer moving and towing customers with a damage waiver, cargo protection, and medical and life insurance coverage; Safestor that protects storage customers from loss on their goods in storage; Safestor Mobile, which protects customers stored belongings; and Safemove Plus, which provides rental customers with a layer of primary liability protection. The company's Life Insurance segment provides life and health insurance products primarily to the senior market through the direct writing and reinsuring of life insurance, medicare supplement, and annuity policies. The company was formerly known as AMERCO. U-Haul Holding Company was founded in 1945 and is based in Reno, Nevada.

More news about Amerco.

2. Petroleo Brasileiro (PBR)

Shares of Petroleo Brasileiro dropped by a staggering 12.57% in from $11.46 to $10.02 at 19:21 EST on Tuesday, after three sequential sessions in a row of losses. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

Petróleo Brasileiro S.A. – Petrobras explores for, produces, and sells oil and gas in Brazil and internationally. The company operates through Exploration and Production; Refining, Transportation and Marketing; Gas and Power; and Corporate and Other Businesses segments. It engages in prospecting, drilling, refining, processing, trading, and transporting crude oil from producing onshore and offshore oil fields, and shale or other rocks, as well as oil products, natural gas, and other liquid hydrocarbons. The Exploration and Production segment explores, develops, and produces crude oil, natural gas liquids, and natural gas primarily for supplies to the domestic refineries. The Refining, Transportation and Marketing segment engages in the refining, logistics, transport, marketing, and trading of crude oil and oil products; exportation of ethanol; and extraction and processing of shale, as well as holding interests in petrochemical companies. The Gas and Power segment is involved in the logistic and trading of natural gas and electricity; transportation and trading of LNG; generation of electricity through thermoelectric power plants; holding interests in transportation and distribution of natural gas; and fertilizer production and natural gas processing business. The Corporate and Other Businesses segment produces biodiesel and its co-products, and ethanol; and distributes oil products. Petróleo Brasileiro S.A. – Petrobras was incorporated in 1953 and is headquartered in Rio de Janeiro, Brazil.

Moving Average

Petroleo Brasileiro’s value is under its 50-day moving average of $11.09 and way below its 200-day moving average of $12.23.

Sales Growth

Petroleo Brasileiro’s sales growth is 24.3% for the current quarter and negative 4.1% for the next.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is 123.1% and a drop 21.3% for the next.

More news about Petroleo Brasileiro.

3. Ecopetrol S.A. (EC)

Shares of Ecopetrol S.A. fell 1.37% in from $10.33 to $10.19 at 19:21 EST on Tuesday, after four sequential sessions in a row of losses. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

Ecopetrol S.A. operates as an integrated energy company. The company operates through four segments: Exploration and Production; Transport and Logistics; Refining, Petrochemical and Biofuels; and Electric Power Transmission and Toll Roads Concessions. It engages in the exploration and production of oil and gas; transportation of crude oil, motor fuels, fuel oil, and other refined products, including diesel, jet, and biofuels; processing and refining crude oil; distribution of natural gas and LPG; sale of refined and petrochemical products; supplying of electric power transmission services; design, development, construction, operation, and maintenance of road and energy infrastructure projects; and supplying of information technology and telecommunications services. As of December 31, 2021, the company had approximately 9,127 kilometers of crude oil and multi-purpose pipelines. It also produces and commercializes polypropylene resins and compounds, and masterbatches; and offers industrial service sales to customers and specialized management services. It has operations in Colombia, the United States, Asia, Central America and the Caribbean, Europe, South America, and internationally. The company was formerly known as Empresa Colombiana de Petróleos and changed its name to Ecopetrol S.A. in June 2003. Ecopetrol S.A. was incorporated in 1948 and is based in Bogotá, Colombia.

More news about Ecopetrol S.A..

4. Eli Lilly and Company (LLY)

Shares of Eli Lilly and Company rose 0.82% in from $328.41 to $331.10 at 19:21 EST on Tuesday, following the last session’s upward trend. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 33.2% and positive 49.6% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Eli Lilly and Company’s stock is considered to be overbought (>=80).

Sales Growth

Eli Lilly and Company’s sales growth is negative 13% for the ongoing quarter and 12.3% for the next.

Moving Average

Eli Lilly and Company’s worth is under its 50-day moving average of $336.51 and below its 200-day moving average of $333.00.

More news about Eli Lilly and Company.

5. Ringcentral (RNG)

Shares of Ringcentral fell by a staggering 25.41% in from $39.52 to $29.48 at 19:21 EST on Tuesday, after five successive sessions in a row of losses. NYSE is jumping 1.41% to $14,985.95, following the last session’s upward trend.

RingCentral, Inc. provides software-as-a-service solutions that enable businesses to communicate, collaborate, and connect in North America. The company offers business cloud communications and contact center solutions based on its Message Video Phone? platform. Its products include RingCentral Office that provides communication and collaboration across various modes, including high-definition voice, video, SMS, messaging and collaboration, conferencing, online meetings, and fax; RingCentral Contact Center, a collaborative contact center solution that delivers omni-channel; and RingCentral Engage Digital, a digital customer engagement platform that allows enterprises to interact with their customers. The company's products also comprise RingCentral Engage Voice, a cloud-based outbound/blended customer engagement platform for midsize and enterprise companies; RingCentral Video, a video meeting service which includes our RCV video and team messaging capabilities and offers video and audio conferencing, file sharing, contact, task, and calendar management. In addition, it offers RingCentral Professional, a cloud based virtual telephone service that provides inbound call answering and management services for professionals; and RingCentral Fax that provides online fax capabilities. The company serves a range of industries, including financial services, education, healthcare, legal services, real estate, retail, technology, insurance, construction, hospitality, and state and local government, as well as others. It sells its products through a network of direct sales representatives, as well as sales agents, resellers, and channel partners. RingCentral, Inc. has strategic partnerships with Alcatel-Lucent Enterprise; and Vodafone Business. The company was incorporated in 1999 and is headquartered in Belmont, California.

Yearly Top and Bottom Value

Ringcentral’s stock is valued at $29.48 at 19:21 EST, way under its 52-week high of $129.72 and higher than its 52-week low of $28.00.

Revenue Growth

Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 1.91B for the twelve trailing months.

Sales Growth

Ringcentral’s sales growth is 17.6% for the ongoing quarter and 16.4% for the next.

More news about Ringcentral.

6. Kodak (KODK)

Shares of Kodak jumped 5.71% in from $3.68 to $3.89 at 19:21 EST on Tuesday, following the last session’s downward trend. NYSE is jumping 1.41% to $14,985.95, following the last session’s upward trend.

Eastman Kodak Company provides hardware, software, consumables, and services to customers in the commercial print, packaging, publishing, manufacturing, and entertainment markets worldwide. The company operates through Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment offers digital offset plate and computer-to-plate imaging solutions to commercial industries, including commercial print, direct mail, book publishing, newspapers and magazines, and packaging. The Digital Printing segment provides electrophotographic printing solutions, such as The ASCEND and NEXFINITY printers; prosper products, including the PROSPER 6000 Press, PROSPER Writing Systems, PROSPER press systems, and PROSPER components; versamark products; and PRINERGY workflow production software. The Advanced Materials and Chemicals segment engages in industrial film and chemicals, motion picture, and advanced materials and functional printing businesses. This segment also comprises the Kodak Research Laboratories, which conducts research, develops new product or new business opportunities, and files patent applications for its inventions and innovations, as well as manages licensing of its intellectual property to third parties. The Brand segment engages in the licensing of Kodak brand to third parties. The company engages in the operation of Eastman Business Park, a technology center and industrial complex. It sells its products and services through direct sales, third party resellers, dealers, channel partners, and distributors. Eastman Kodak Company was founded in 1880 and is headquartered in Rochester, New York.

More news about Kodak.

7. Novartis AG (NVS)

Shares of Novartis AG slid 4% in from $87.19 to $83.70 at 19:21 EST on Tuesday, after two sequential sessions in a row of gains. NYSE is jumping 1.41% to $14,985.95, following the last session’s upward trend.

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

More news about Novartis AG.

8. AbbVie (ABBV)

Shares of AbbVie rose 3.71% in from $151.31 to $156.92 at 19:21 EST on Tuesday, following the last session’s upward trend. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.3%, now sitting on 57.82B for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 5.7% and a negative 10.4%, respectively.

More news about AbbVie.

9. argenx SE (ARGX)

Shares of argenx SE slid 3.98% in from $372.53 to $357.70 at 19:21 EST on Tuesday, after three consecutive sessions in a row of gains. NASDAQ is rising 1.58% to $11,860.11, following the last session’s upward trend.

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1961.8%, now sitting on 285.68M for the twelve trailing months.

More news about argenx SE.

10. Generac Holdlings (GNRC)

Shares of Generac Holdlings slid by a staggering 10.26% in from $128.11 to $114.97 at 19:21 EST on Tuesday, after four successive sessions in a row of losses. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

Generac Holdings Inc. designs, manufactures, and sells power generation equipment, energy storage systems, and other power products for the residential, and light commercial and industrial markets worldwide. The company offers engines, alternators, batteries, electronic controls, steel enclosures, and other components. It also provides residential automatic standby generators ranging in output from 7.5kW to 150kW; air-cooled engine residential standby generators ranging from 7.5kW to 26kW; liquid-cooled engine generators with outputs ranging from 22kW to 150kW; and Mobile Link, a remote monitoring system for home standby generators. In addition, the company offers various portable generators ranging in size from 800W to 17.5kW; outdoor power equipment, such as trimmers, field and brush mowers, log splitters, stump grinders, chipper shredders, lawn and leaf vacuums, pressure washers, and water pumps; and clean energy solution under the PWRcell and PWRview brands. Further, it provides light towers, mobile generators, and mobile energy storage systems; commercial mobile pumps and dust-suppression equipment; various gaseous-engine control systems and accessories; light-commercial standby generators ranging from 22kW to 150kW and related transfer switches providing three-phase power for small and mid-sized businesses; and industrial generators ranging in output from 10kW to 3,250kW used as emergency backup for healthcare, telecom, datacom, commercial office, retail, municipal, and manufacturing markets. Additionally, the company sells aftermarket service parts and product accessories to dealers. It distributes its products through independent residential dealers, industrial distributors and dealers, national and regional retailers, e-commerce partners, electrical, HVAC and solar wholesalers, catalogs, equipment rental companies and distributors, and solar installers; and directly to end users. The company was founded in 1959 and is headquartered in Waukesha, Wisconsin.

Yearly Top and Bottom Value

Generac Holdlings’s stock is valued at $114.97 at 19:21 EST, way under its 52-week high of $328.60 and way higher than its 52-week low of $86.29.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Generac Holdlings’s stock is considered to be overbought (>=80).

More news about Generac Holdlings.

11. Franco (FNV)

Shares of Franco rose 6.51% in from $132.45 to $141.07 at 19:21 EST on Tuesday, after five consecutive sessions in a row of gains. NYSE is jumping 1.41% to $14,985.95, following the last session’s upward trend.

Franco-Nevada Corporation operates as a gold-focused royalty and streaming company in Latin America, the United States, Canada, and internationally. It operates in two segments, Mining and Energy. The company manages its portfolio with a focus on precious metals, such as gold, silver, and platinum group metals; and energy comprising oil, gas, and natural gas liquids. The company was founded in 1983 and is headquartered in Toronto, Canada.

More news about Franco.

12. Brandywine Realty Trust (BDN)

Shares of Brandywine Realty Trust dropped by a staggering 37.79% in from $7.57 to $4.71 at 19:21 EST on Tuesday, following the last session’s upward trend. NYSE is jumping 1.41% to $14,985.95, following the last session’s upward trend.

Brandywine Realty Trust (NYSE: BDN) is one of the largest, publicly traded, full-service, integrated real estate companies in the United States with a core focus in the Philadelphia, Austin and Washington, D.C. markets. Organized as a real estate investment trust (REIT), we own, develop, lease and manage an urban, town center and transit-oriented portfolio comprising 175 properties and 24.7 million square feet as of December 31, 2020 which excludes assets held for sale. Our purpose is to shape, connect and inspire the world around us through our expertise, the relationships we foster, the communities in which we live and work, and the history we build together.

Yearly Top and Bottom Value

Brandywine Realty Trust’s stock is valued at $4.71 at 19:21 EST, under its 52-week low of $5.14.

Sales Growth

Brandywine Realty Trust’s sales growth is 0.7% for the ongoing quarter and 3.4% for the next.

Moving Average

Brandywine Realty Trust’s value is way under its 50-day moving average of $6.27 and way below its 200-day moving average of $7.57.

Volatility

Brandywine Realty Trust’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.88%, a negative 2.27%, and a positive 2.13%.

Brandywine Realty Trust’s highest amplitude of average volatility was 3.33% (last week), 2.42% (last month), and 2.13% (last quarter).

More news about Brandywine Realty Trust.

13. Take-Two Interactive Software (TTWO)

Shares of Take-Two Interactive Software jumped 5.9% in from $112.51 to $119.15 at 19:21 EST on Tuesday, after three successive sessions in a row of gains. NASDAQ is jumping 1.58% to $11,860.11, following the last session’s upward trend.

Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment solutions for consumers worldwide. The company offers its products under the Rockstar Games, 2K, Private Division, and T2 Mobile Games names. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead Redemption names; and offers episodes and content, as well as develops brands in other genres, including the LA Noire, Bully, and Manhunt franchises. The company also publishes various entertainment properties across various platforms and a range of genres, such as shooter, action, role-playing, strategy, sports, and family/casual entertainment under the BioShock, Mafia, Sid Meier's Civilization, XCOM series, and Borderlands. In addition, it publishes sports simulation titles comprising NBA 2K series, a basketball video game; the WWE 2K professional wrestling series; and PGA TOUR 2K. Further, the company offers Kerbal Space Program, OlliOlli World, and The Outer Worlds and Ancestors: the Humankind Odyssey under Private Division; and free-to-play mobile games, such as Dragon City, Monster Legends, Two Dots, and Top Eleven. Its products are designed for console gaming systems, including PlayStation 4 and PlayStation 5; Xbox One; the Nintendo's Switch; personal computers; and mobile comprising smartphones and tablets. The company provides its products through physical retail, digital download, online platforms, and cloud streaming services. Take-Two Interactive Software, Inc. was incorporated in 1993 and is based in New York, New York.

Moving Average

Take-Two Interactive Software’s worth is above its 50-day moving average of $110.71 and above its 200-day moving average of $115.95.

Revenue Growth

Year-on-year quarterly revenue growth grew by 55.9%, now sitting on 4.83B for the twelve trailing months.

More news about Take-Two Interactive Software.

14. Match Group (MTCH)

Shares of Match Group fell by a staggering 13.62% in from $44.45 to $38.40 at 19:21 EST on Tuesday, after five consecutive sessions in a row of gains. NASDAQ is rising 1.58% to $11,860.11, following the last session’s upward trend.

Match Group, Inc. provides dating products worldwide. The company's portfolio of brands includes Tinder, Match, Meetic, OkCupid, Hinge, Pairs, PlentyOfFish, and OurTime, as well as a various other brands. The company was incorporated in 1986 and is based in Dallas, Texas.

Volatility

Match Group’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.33%, a negative 0.73%, and a positive 2.18%.

Match Group’s highest amplitude of average volatility was 0.55% (last week), 2.00% (last month), and 2.18% (last quarter).

More news about Match Group.

15. NetEase (NTES)

Shares of NetEase jumped 0.27% in from $85.84 to $86.07 at 19:21 EST on Tuesday, following the last session’s downward trend. NASDAQ is rising 1.58% to $11,860.11, following the last session’s upward trend.

NetEase, Inc. provides online services focusing on diverse content, community, communication, and commerce in the Peoples' Republic of China and internationally. The company operates in three segments: Online Game Services, Youdao, Cloud Music, and Innovative Businesses and Others. It develops and operates PC and mobile games, as well as offers games licensed from other game developers. The company's products and services include Youdao Dictionary, an online knowledge tool; Youdao Translation, a tool specifically designed to support translation needs of business and leisure travelers; U-Dictionary, an online dictionary and translation app; Youdao Kids' Dictionary, a smart and fun tool; smart devices, such as Youdao Dictionary Pen, Youdao Listening Pod, Youdao Smart Lamp, Youdao Pocket Translator, and Youdao Super Dictionary; online courses; interactive learning apps; enterprise services, such as Youdao Smart Learning Terminal, a device that automates paper-based homework processing and provides learning diagnosis through artificial intelligence technology at schools; and Youdao Smart Cloud, a cloud-based platform that allows third-party app developers, smart device brands and manufacturers to access advanced optical character recognition capabilities and neural machine translation engine. Its products and services also include NetEase Cloud Music, a music streaming platform; Yanxuan, an e-commerce platform, which sells private label products, including consumer electronics, food, apparel, homeware, kitchenware, and other general merchandise; NetEase Media, an internet media platform; NetEase Mail, an email service; NetEase CC Live streaming, a live streaming platform with a focus on game broadcasting; and NetEase Pay, a payment platform. The company was formerly known as NetEase.com, Inc. and changed its name to NetEase, Inc. in March 2012. NetEase, Inc. was founded in 1997 and is headquartered in Hangzhou, the People's Republic of China.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 21.9% and positive 7% for the next.

More news about NetEase.

16. Virgin Galactic (SPCE)

Shares of Virgin Galactic fell by a staggering 53.86% in from $8.97 to $4.14 at 19:21 EST on Tuesday, after five successive sessions in a row of losses. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico. Virgin Galactic Holdings, Inc. was a former subsidiary of Virgin Orbit Holdings, Inc.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Virgin Galactic’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 70.3%, now sitting on 1.58M for the twelve trailing months.

Yearly Top and Bottom Value

Virgin Galactic’s stock is valued at $4.14 at 19:21 EST, way under its 52-week high of $11.25 and way higher than its 52-week low of $3.24.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 64.5% and a negative 41.7%, respectively.

More news about Virgin Galactic.

17. DocuSign (DOCU)

Shares of DocuSign slid 9.9% in from $65.11 to $58.66 at 19:21 EST on Tuesday, after two consecutive sessions in a row of losses. NASDAQ is jumping 1.58% to $11,860.11, following the last session’s upward trend.

DocuSign, Inc. provides electronic signature software in the United States and internationally. The company provides e-signature solution that enables businesses to digitally prepare, sign, act on, and manage agreements. It also offers CLM, which automates workflows across the entire agreement process; Insights that use artificial intelligence (AI) to search and analyze agreements by legal concepts and clauses; Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce; Negotiate for Salesforce that supports for approvals, document comparisons, and version control; Analyzer, which helps customers understand what they're signing before they sign it; and CLM+ that provide AI-driven contract lifecycle management. The company provides Guided Forms, which enable complex forms to be filled via an interactive and step-by-step process; Click that supports no-signature-required agreements for standard terms and consents; Identify, a signer-identification option for checking government-issued IDs; Standards-Based Signatures, which support signatures that involve digital certificates; Payments that enables customers to collect signatures and payment; Remote Online Notary is a solution using audio-visual and identify verification technologies to enable notarization; and Monitor using advanced analytics to track DocuSign eSignature web, mobile, and API account. It offers industry-specific cloud offerings, including Rooms for Real Estate that provides a way for brokers and agents to manage the entire real estate transaction digitally; Rooms for Mortgage, which offers digital workspace to create and close mortgages; FedRAMP, an authorized version of DocuSign eSignature for U.S. federal government agencies; and life sciences modules that support compliance with the electronic signature practices. The company sells its products through direct, partner-assisted, and Web-based sales. It serves enterprise, commercial, and small businesses. The company was incorporated in 2003 and is headquartered in San Francisco, California.

Moving Average

DocuSign’s worth is under its 50-day moving average of $60.16 and below its 200-day moving average of $58.95.

More news about DocuSign.

18. Zai Lab (ZLAB)

Shares of Zai Lab slid by a staggering 15.12% in from $38.25 to $32.47 at 19:21 EST on Tuesday, after two consecutive sessions in a row of losses. NASDAQ is jumping 1.58% to $11,860.11, following the last session’s upward trend.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Moving Average

Zai Lab’s worth is way below its 50-day moving average of $39.78 and way below its 200-day moving average of $36.99.

Volatility

Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.15%, a negative 1.67%, and a positive 4.54%.

Zai Lab’s highest amplitude of average volatility was 5.49% (last week), 5.06% (last month), and 4.54% (last quarter).

More news about Zai Lab.

19. QuantumScape (QS)

Shares of QuantumScape dropped by a staggering 30.67% in from $11.38 to $7.89 at 19:21 EST on Tuesday, after five sequential sessions in a row of gains. NYSE is jumping 1.41% to $14,985.95, following the last session’s upward trend.

QuantumScape Corporation, a development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, QuantumScape’s stock is considered to be oversold (<=20).

More news about QuantumScape.

20. ONE Gas (OGS)

Shares of ONE Gas slid 5.48% in from $82.04 to $77.54 at 19:21 EST on Tuesday, after two sequential sessions in a row of gains. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

ONE Gas, Inc., together with its subsidiaries, operates as a regulated natural gas distribution utility company in the United States. The company operates through three divisions: Oklahoma Natural Gas, Kansas Gas Service, and Texas Gas Service. It provides natural gas distribution services to 2.2 million customers in three states. It serves residential, commercial, and transportation customers. As of December 31, 2021, it operated approximately 41,600 miles of distribution mains; and 2,400 miles of transmission pipelines, as well as had 51.4 billion cubic feet of natural gas storage capacity. ONE Gas, Inc. was founded in 1906 and is headquartered in Tulsa, Oklahoma.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONE Gas’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 31.2%, now sitting on 2.35B for the twelve trailing months.

Moving Average

ONE Gas’s worth is under its 50-day moving average of $79.66 and below its 200-day moving average of $79.39.

More news about ONE Gas.

21. Biogen (BIIB)

Shares of Biogen fell 4.63% in from $278.97 to $266.05 at 19:21 EST on Tuesday, following the last session’s upward trend. NASDAQ is jumping 1.58% to $11,860.11, following the last session’s upward trend.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Yearly Top and Bottom Value

Biogen’s stock is valued at $266.05 at 19:21 EST, way under its 52-week high of $311.88 and way higher than its 52-week low of $187.16.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Biogen’s stock is considered to be oversold (<=20).

More news about Biogen.

22. Astrazeneca (AZN)

Shares of Astrazeneca dropped 2.89% in from $69.02 to $67.03 at 19:21 EST on Tuesday, following the last session’s upward trend. NYSE is rising 1.41% to $14,985.95, following the last session’s upward trend.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 7.4% and positive 9.3% for the next.

More news about Astrazeneca.

23. Hologic (HOLX)

Shares of Hologic fell 3.59% in from $82.83 to $79.86 at 19:21 EST on Tuesday, following the last session’s upward trend. NASDAQ is jumping 1.58% to $11,860.11, following the last session’s upward trend.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Sales Growth

Hologic’s sales growth is negative 33.2% for the current quarter and negative 4.3% for the next.

Volatility

Hologic’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.33%, a negative 0.21%, and a positive 1.02%.

Hologic’s highest amplitude of average volatility was 1.15% (last week), 0.92% (last month), and 1.02% (last quarter).

Moving Average

Hologic’s value is under its 50-day moving average of $80.88 and above its 200-day moving average of $73.07.

Revenue Growth

Year-on-year quarterly revenue growth declined by 27%, now sitting on 4.47B for the twelve trailing months.

More news about Hologic.